GSK Initiates P-III Study of GSK3511294 (GSK’294) for the Treatment of Severe Asthma

 GSK Initiates P-III Study of GSK3511294 (GSK’294) for the Treatment of Severe Asthma

GSK Initiates P-III Study of GSK3511294 (GSK’294) for the Treatment of Severe Asthma

Shots:

  • The first patient has been dosed in the P-III SWIFT-2 trial assessing the safety and efficacy of GSK3511294 (GSK’294) in SEA
  • The planned P-III program involves three studies, SWIFT 1, SWIFT 2 and the NIMBLE study that will assess the efficacy and safety of GSK’294 in ~2,450 patients with severe eosinophilic asthma
  • GSK’294 (SC, every 6mos.) is an anti-IL-5 mAb, currently in development for the treatment of SEA and has progressed from P-I to P-III studies in three and a half years

Click here ­to­ read full press release/ article | Ref: GSK | Image: News Medical

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post